199 related articles for article (PubMed ID: 26016637)
1. [Pluripotent stem cells as a source for T cell research and clinical application].
Ueda T; Kaneko S
Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(2):101-8. PubMed ID: 26016637
[TBL] [Abstract][Full Text] [Related]
2. [Immune cell therapy using iPS cells].
Yano H; Kaneko S
Rinsho Ketsueki; 2018; 59(2):225-231. PubMed ID: 29515078
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
4. Reprogramming away from the exhausted T cell state.
Karagiannis P; Iriguchi S; Kaneko S
Semin Immunol; 2016 Feb; 28(1):35-44. PubMed ID: 26589493
[TBL] [Abstract][Full Text] [Related]
5. Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.
Schlenker R; Olguín-Contreras LF; Leisegang M; Schnappinger J; Disovic A; Rühland S; Nelson PJ; Leonhardt H; Harz H; Wilde S; Schendel DJ; Uckert W; Willimsky G; Noessner E
Cancer Res; 2017 Jul; 77(13):3577-3590. PubMed ID: 28533272
[TBL] [Abstract][Full Text] [Related]
6. Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer.
Hombach AA; Abken H
Immunotherapy; 2013 Jul; 5(7):677-81. PubMed ID: 23829616
[No Abstract] [Full Text] [Related]
7. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
[TBL] [Abstract][Full Text] [Related]
8. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
Houot R; Schultz LM; Marabelle A; Kohrt H
Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
[TBL] [Abstract][Full Text] [Related]
9. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.
Duong CP; Yong CS; Kershaw MH; Slaney CY; Darcy PK
Mol Immunol; 2015 Oct; 67(2 Pt A):46-57. PubMed ID: 25595028
[TBL] [Abstract][Full Text] [Related]
10. Permissive expansion and homing of adoptively transferred T cells in tumor-bearing hosts.
Perez C; Jukica A; Listopad JJ; Anders K; Kühl AA; Loddenkemper C; Blankenstein T; Charo J
Int J Cancer; 2015 Jul; 137(2):359-71. PubMed ID: 25530110
[TBL] [Abstract][Full Text] [Related]
11. Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer.
Magee MS; Snook AE
Discov Med; 2014 Nov; 18(100):265-71. PubMed ID: 25425467
[TBL] [Abstract][Full Text] [Related]
12. Exploiting cytokines in adoptive T-cell therapy of cancer.
Petrozziello E; Sturmheit T; Mondino A
Immunotherapy; 2015; 7(5):573-84. PubMed ID: 26065481
[TBL] [Abstract][Full Text] [Related]
13. 'Off-the-shelf' immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes.
Ando M; Nakauchi H
Exp Hematol; 2017 Mar; 47():2-12. PubMed ID: 27826124
[TBL] [Abstract][Full Text] [Related]
14. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.
Oren R; Hod-Marco M; Haus-Cohen M; Thomas S; Blat D; Duvshani N; Denkberg G; Elbaz Y; Benchetrit F; Eshhar Z; Stauss H; Reiter Y
J Immunol; 2014 Dec; 193(11):5733-43. PubMed ID: 25362181
[TBL] [Abstract][Full Text] [Related]
15. Cancer-eating immune cells kitted out with CARs.
Dolgin E
Nat Biotechnol; 2020 May; 38(5):509-511. PubMed ID: 32393919
[No Abstract] [Full Text] [Related]
16. Toward the development of true "off-the-shelf" synthetic T-cell immunotherapy.
Iriguchi S; Kaneko S
Cancer Sci; 2019 Jan; 110(1):16-22. PubMed ID: 30485606
[TBL] [Abstract][Full Text] [Related]
17. Adoptive T-cell immunotherapy of cancer.
Li Q; Chang AE
Cytokines Cell Mol Ther; 1999 Jun; 5(2):105-17. PubMed ID: 10515683
[TBL] [Abstract][Full Text] [Related]
18. Adoptive T-cell therapy for cancer: The era of engineered T cells.
Bonini C; Mondino A
Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
[TBL] [Abstract][Full Text] [Related]
19. Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells.
Islam SMR; Maeda T; Tamaoki N; Good ML; Kishton RJ; Paria BC; Yu Z; Bosch-Marce M; Bedanova NM; Liu C; Kruhlak MJ; Restifo NP; Vizcardo R
Cancer Res Commun; 2023 May; 3(5):917-932. PubMed ID: 37377887
[TBL] [Abstract][Full Text] [Related]
20. Targeting glycosylation of PD-1 to enhance CAR-T cell cytotoxicity.
Shi X; Zhang D; Li F; Zhang Z; Wang S; Xuan Y; Ping Y; Zhang Y
J Hematol Oncol; 2019 Nov; 12(1):127. PubMed ID: 31783892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]